Technology Platforms for Precision Medicine
P4Health’s five technological platforms form the operational core of the center. They are designed as an integrated system—each platform handles a distinct part of the research workflow, and together they cover the complete path from patient sample to biological insight to therapeutic candidate.
The platforms support P4Health’s own research groups and are progressively being opened for collaborative projects with academic partners, clinical institutions, and industry.
P1 — Clinical and Biobanking Platform
The Clinical and Biobanking Platform connects P4Health to clinical sites and to patients. It manages the collection, processing, anonymization, and long-term storage of biological samples—including tumor tissue, blood, urine, and other material—and develops the data infrastructure needed to make these samples scientifically usable at scale.
The platform works closely with the affiliated Biobank Research Group led by dr hab. Patrycja Gazińska, which operates one of the largest repositories of human biological material in Poland. P1 also coordinates P4Health’s Patient and Public Involvement and Engagement (PPIE) program, ensuring that the research agenda reflects genuine patient needs and maintains public trust in biobanking.
Core capabilities: biological sample collection and processing, cryogenic storage at −80°C and −150°C, clinical data coordination, PPIE program management, bioethics compliance, GDPR-compliant data anonymization, collaboration within BBMRI.pl and BBMRI-ERIC.
P2 — Spatial and Computational Pathology Platform
The Spatial and Computational Pathology Platform provides histopathological analysis capabilities combining digital pathology with spatial transcriptomics and spatial proteomics. It can detect and quantify thousands of molecules—RNA or protein—in a single tissue section while preserving spatial information about where those molecules appear within the tissue.
This resolution is transforming cancer research: it allows researchers to map how tumor cells interact with immune cells, stromal cells, and vasculature in their native microenvironment. P2 includes tissue scanning with integrated diagnostic reporting software, multiplex immunofluorescence staining, and AI-assisted image analysis pipelines developed in collaboration with King’s College London.
Core capabilities: digital pathology scanning, spatial transcriptomics, spatial proteomics, multiplex immunofluorescence, AI-assisted image analysis, monoclonal antibody production, digital tissue data catalog.
P3 — Bioanalytics Platform
The Bioanalytics Platform provides multiomics profiling: genomics, proteomics, metabolomics, and digital phenotyping. It translates biological samples into comprehensive molecular profiles capturing the state of disease at high resolution.
P3 uses AI-based approaches to integrate data from multiple modalities—genomic sequences, protein expression, metabolite measurements, imaging data, and clinical records—into coherent representations of patient-specific disease states. This is particularly valuable in psychiatry and neurology, where objective molecular markers remain scarce and patient stratification for clinical trials is a persistent challenge.
Core capabilities: whole-genome and targeted sequencing, quantitative proteomics and metabolomics by LC-MS/NMR, AI-assisted data integration, digital phenotyping, patient stratification support.
P4 — Functional Validation in Disease Models Platform
The Functional Validation in Disease Models Platform houses the experimental systems for testing hypotheses generated in other platforms. It covers both in vitro and in vivo disease models, allowing researchers to move from molecular findings to biological validation.
In oncology, the platform works primarily with organoid models derived from patient tumor tissue—three-dimensional structures that preserve the heterogeneity and key properties of the original tumor. In neuroscience and neuropsychiatry, it uses iPSC-derived neuronal models: human cells reprogrammed from patients’ own material and differentiated into neurons or glial cells. The platform also develops in vivo models for validation, including patient-derived xenograft (PDX) models and humanized animal models, developed in collaboration with CERBM’s Mouse Clinic. AI-assisted behavioral phenotyping tools developed under the Horizon Europe SAME-NeuroID project are integrated into this workflow.
Core capabilities: patient-derived tumor organoids, iPSC-derived neurons and glia, brain organoids, PDX models, humanized mouse models, CRISPR-based gene editing, AI-assisted behavioral phenotyping.
P5 — Cell Engineering and Cell-based Therapies Platform
The Cell Engineering and Cell-based Therapies Platform focuses on developing innovative cell-based approaches to treatment. It uses genome manipulation tools—including CRISPR/Cas9 with expertise from CERBM, and base and prime editing developed in-house—to engineer cells with targeted properties.
The platform works on optimizing cell culture techniques for large-scale expansion while maintaining cell function, and is developing processes toward GMP (Good Manufacturing Practice) standards for future Advanced Therapy Medicinal Product (ATMP) production.
Core capabilities: CRISPR/Cas9 and base editing, T cell engineering, optimized cell expansion protocols, GMP-compliant process development, ATMP production pathway.
Interested in working with our platforms?
P4Health’s platforms are progressively being opened for collaborative use by academic researchers, clinical institutions, and industry partners. For inquiries, contact: p4health@port.lukasiewicz.gov.pl
P4Health is part of Łukasiewicz – PORT, which also offers a broad range of analytical, bioanalytical, and research services.